1Buy.AI | $3,900,000 | (Feb 3, 2026)
DexMat | $5,000,000 | (Feb 3, 2026)
PranaX
United States
- Houston, Texas
- 03/02/2026
- Series A
- $17,000,000
PranaX is a regenerative biological products company dedicated to harnessing stem cell-derived exosomes through evidence-based science. We aim to develop exosomes as natural, physician-directed solutions for regenerative dermatology and wellness applications. The company’s overarching mission is to unlock the properties of exosomes to promote wellness and lead individuals towards healthier, more fulfilling lives.
Our exosomes at a glance:
• We use an exclusive technology license from MD Anderson, a leading-edge cancer research center known as a premier provider of exosome-driven therapy.
• Production takes place at our own FDA-registered, GMP facility.
• Leveraging multiple licensed patents allows us to develop anti-aging therapeutics.
• Because we manufacture our stem cell exosomes, we can manage quality assurance and replenish supply to meet demand.
- Industry Biotechnology Research
- Website https://www.pranax.com/
- LinkedIn https://www.linkedin.com/company/pranax/?viewAsMember=true
Related People
Phillip MaderiaFounder
United States -
Boston, Massachusetts
Over 30 years of biopharmaceutical manufacturing and engineering experience with 27 years of management experience. A diverse background in the commercial manufacturing, validation, control system and process engineering, employee engagement and community development.
Prenosis | $20,000,000 | (Feb 3, 2026)
CloudForge AI | $3,950,000 | (Feb 3, 2026)
Linq | $20,000,000 | (Feb 3, 2026)
Breezy | $10,000,000 | (Feb 3, 2026)
JJG Machining Group | $30,000,000 | (Feb 3, 2026)
BizTrip AI | $1,500,000 | (Feb 3, 2026)
Co-reactive | $7,754,157 | (Jan 30, 2026)
Checkbox | $23,000,000 | (Jan 30, 2026)